STOCK TITAN

[IRANNOTICE] NOVARTIS AG SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
IRANNOTICE

Rhea-AI Filing Summary

Analyzing...





Novartis AG
P.O. Box
CH 4002 Basel







US Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549



Basel, February 4, 2026


 
Re:
Notice of disclosure filed in Annual Report on Form 20-F under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934


Ladies and Gentlemen:

Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934, as amended, notice is hereby provided that Novartis AG has made disclosure pursuant to those provisions in its Annual Report on Form 20-F for the year ended December 31, 2025, which was filed with the Securities and Exchange Commission on February 4, 2026.



Respectfully submitted,

Novartis AG




/s/ Karen L. Hale

/s/ Harry Kirsch
 
Karen L. Hale
Chief Legal & Compliance Officer of Novartis
 
Harry Kirsch
Chief Financial Officer of Novartis
 


Novartis

NYSE:NVS

NVS Rankings

NVS Latest News

NVS Latest SEC Filings

NVS Stock Data

293.40B
1.92B
0%
7.05%
0.23%
Drug Manufacturers - General
Healthcare
Link
Switzerland
Basel